- Amplia Therapeutics (ATX) receives grant funding to support research collaboration with Australia’s national science agency, CSIRO
- The company will work with CSIRO to develop formulations of its small molecule FAK inhibitors that can be applied directly to wounds and burns to aid healing and reduce scarring
- ATX CEO and MD Dr Chris Burns says there is growing evidence that “inhibition of FAK in the skin may accelerate wound healing and limit scar formation”
- The global wound healing market is estimated to be more than US$20 billion (A$30 billion), with the market for scar treatments of a similar size
- Shares in ATX are down 5.88 per cent and trading at eight cents at 11:15 am AEST
Amplia Therapeutics (ATX) has secured grant funding to support research collaboration with Australia’s national science agency, CSIRO.
The company announced it will collaborate with CSIRO to develop formulations of its small molecule FAK inhibitors that can be applied directly to wounds and burns to aid healing and reduce scarring.
Amplia CEO and Managing Director Dr Chris Burns said the team are looking forward to working with CSIRO.
“There is growing evidence in the scientific literature that inhibition of FAK in the skin may accelerate wound healing and limit scar formation,” he said.
“We are looking forward to working with CSIRO to develop a formulation of our proprietary FAK inhibitors so we can determine their suitability for use in wound healing.”
The company reported over-activity of Focal Adhesion Kinase (FAK) in fibrocast cells in wounds is responsible for the laying down and cross-linking of collagen, which results in the formation of scar tissue.
The global wound healing market is estimated to be worth more than US$20 billion (A$30 billion), while the market for scar treatments is a similar size.
Shares in ATX were down 5.88 per cent and trading at eight cents at 11:15 am AEST.